Form 4: CG Oncology CFO Corleen M. Roche Acquires Stock Options
SEC Form 4 Filing
CFO of CG Oncology, Corleen M. Roche, reports acquisition of employee stock options.
Summary
- Corleen M. Roche, CFO of CG Oncology, filed a Form 4 with the SEC.
- The filing reports the acquisition of 143,907 employee stock options with an exercise price of $20.11.
- The options vest monthly over a four-year period, commencing on April 15, 2025, contingent upon continuous service.
- The options expire on April 14, 2035.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, indicating standard compensation practices. It doesn't inherently suggest positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- Shareholders may view this as a standard part of executive compensation.
- Employees receiving stock options may be motivated by the potential for future gains.
Key Dates
| Date | Description |
|---|---|
| 04/15/2025 | Date of Earliest Transaction and Vesting Commencement Date |
| 04/16/2025 | Date of Form 4 Filing |
| 04/14/2035 | Expiration Date of Employee Stock Options |
Keywords
Form 4, CG Oncology, Stock Options, Insider Trading, SEC Filing, Corleen M. Roche, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.